Larynx News and Research

RSS

Groundbreaking study looks at how puberty affects voice changes in male singers

The first round of tests have been completed for members of the Cincinnati Boychoir who are part of a joint study with Cincinnati Children's Hospital Medical Center to look at the changing voices of male singers.

17 Apr 2015

Study explores outcomes of thyroid surgery in professional singers

A diagnosis of thyroid cancer can be devastating to professional singers, because surgical removal of the thyroid commonly causes voice changes. Massachusetts Eye and Ear surgeons developed a neural monitoring system to be used intraoperatively to improve outcomes.

25 Mar 2015

MED15 may serve as prognostic marker for HNSCC recurrence

A new study provides the first evidence that the mediator complex subunit 15 (MED15) may play a crucial role in the pathophysiology of head and neck squamous cell carcinoma (HNSCC). MED15 overexpression was found to be associated with higher mortality rates in HNSCC patients with cancer recurrence, particularly in oral cavity/oropharyngeal tumors, according to the study published in The American Journal of Pathology.

21 Mar 2015

Somna Therapeutics receives FDA clearance to market REZA BAND UES Assist Device in U.S.

Somna Therapeutics today announced that the U.S. Food and Drug Administration cleared the REZA BAND UES Assist Device for marketing in the U.S. The REZA BAND is a ground-breaking, new, externally-worn, non-medication, non-surgical medical device designed to reduce symptoms of laryngopharyngeal reflux (LPR) by stopping regurgitation of stomach contents through the upper esophageal sphincter (UES).

10 Mar 2015

CPRIT awards research and recruitment grants to improve cancer research

The Cancer Prevention and Research Institute of Texas (CPRIT) has awarded UT Southwestern Medical Center researchers more than $7.5 million in research grants to improve diagnostic and therapeutic services and research relating to cancers of the brain, breast, throat, and bone, as well as to improve scientific understanding of cancer biology.

9 Mar 2015

Isis Pharmaceuticals announces positive results from Phase 1 study of ISIS-PKK Rx for HAE treatment

Isis Pharmaceuticals, Inc. announced today positive results from a Phase 1 study with ISIS-PKKRx. In this study, healthy volunteers treated with ISIS-PKKRx achieved dose-dependent reductions of up to 95 percent in prekallikrein, or PKK. ISIS-PKKRx is a RNA-targeted antisense drug designed to inhibit the production of PKK for the prophylactic treatment of hereditary angioedema (HAE).

24 Feb 2015

New Endoscopic Technique

A flexible wide-field endoscope utilising blue excitation light provides label-free contrast of tissue based on fluorescence lifetime imaging of tissue autofluorescence.

10 Feb 2015

New holistic approach to cancer treatment

The University of Texas MD Anderson Cancer Center and UnitedHealthcare have launched a pilot to explore a new cancer care payment model for head and neck cancers that focuses on quality patient care and outcomes. The collaboration is among the first using bundled payments in a large, comprehensive cancer center.

15 Dec 2014

Study: Five-year survival rate for advanced-stage laryngeal cancer higher than national levels

The five-year survival rate for advanced-stage laryngeal cancer was higher than national levels in a small study at a single academic center performing a high rate of surgical therapy, including a total laryngectomy (removal of the voice box), to treat the disease, despite a national trend toward organ preservation, according to a report published online by JAMA Otolaryngology-Head & Neck Surgery.

28 Nov 2014

Pre-treatment pain intensity predicts survival of patients with head and neck cancer

Pre-treatment pain intensity is an independent survival predictor for patients with head and neck cancer, according to new research published in The Journal of Pain, the peer-reviewed publication of the American Pain Society.

28 Oct 2014

FDA approves Epaned for treatment of symptomatic and asymptomatic heart failure

Silvergate Pharmaceuticals, Inc., focused on the development and commercialization of innovative and safe medicines for children, today announced that the United States Food and Drug Administration approved Epaned for the treatment of symptomatic heart failure and the treatment of asymptomatic left ventricular dysfunction (to decrease the rate of development of overt heart failure and to reduce hospitalization for heart failure).

9 Sep 2014

Socioeconomic status appears to influence type of cancer a person may develop

A new analysis has found that certain cancers are more concentrated in areas with high poverty, while other cancers arise more often in wealthy regions. Also, areas with higher poverty had lower cancer incidence and higher mortality than areas with lower poverty.

28 May 2014

New analysis finds that certain cancers are more concentrated in areas with high poverty

28 May 2014

RUB philosopher assesses suggestions for new healthcare system

Who is supposed to pay for it? The healthcare industry of western industrialised nations has financing problems: technology marches on and makes new, sophisticated treatments possible; at the same time, the population is ageing.

26 May 2014

Isis Pharmaceuticals starts Phase 1 clinical study of ISIS-PKKRx to treat patients with HAE

Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced today that it initiated a Phase 1 clinical study of ISIS-PKKRx. ISIS-PKKRx is an antisense drug in development to treat patients with hereditary angioedemia (HAE).

21 May 2014

$RTOG 9003: Hyperfractionated RT improves overall survival in patients with head and neck cancer$

RTOG 9003: Hyperfractionated RT improves overall survival in patients with head and neck cancer

Patients with locally advanced squamous cell carcinoma of the head and neck treated with hyperfractionated radiation therapy (HFX) experienced improved local-regional control and, with patients censored at five years, improved overall survival with no increase in late toxicity, according to a study published in the May 1, 2014 edition of the International Journal of Radiation Oncology ● Biology ● Physics (Red Journal), the official scientific journal of the American Society for Radiation Oncology (ASTRO).

2 May 2014

FDA approves expanded use Dyax’s KALBITOR in treatment of acute hereditary angioedema

Dyax Corp. today announced that the U.S. Food and Drug Administration (FDA) has approved an expansion of the indication for KALBITOR (ecallantide), a peptide inhibitor of plasma kallikrein used in the treatment of acute hereditary angioedema (HAE) attacks, to include patients 12 years of age and older.

4 Apr 2014

Oropharyngeal cancer patients treated with CRT show decrease in voice and speech quality

Oropharyngeal cancer patients treated with combined chemotherapy and radiation therapy reported a decrease in their voice and speech quality (VSQ) for up to one year after the completion of treatment, according to research presented today at the 2014 Multidisciplinary Head and Neck Cancer Symposium.

21 Feb 2014

CSL Behring enrolls first patient in phase III study of C1-INH for prevention of HAE attacks

CSL Behring today announced it has enrolled the first patient in COMPACT, an international phase III study of a volume-reduced, subcutaneous formulation of C1-esterase inhibitor oncentrate in patients with frequent hereditary angioedema attacks (NCT01912456).

20 Feb 2014

First patient dosed in ADXS-HPV Phase 1/2 study for HPV-associated head and neck cancer

Advaxis, Inc., a leader in developing the next generation of cancer immunotherapies, announced that the first patient has been dosed in a Phase 1/2 "window of opportunity" study being conducted by the Icahn School of Medicine at Mount Sinai. Patients diagnosed with HPV-associated head and neck cancer will receive ADXS-HPV immunotherapy during the "window" of time between initial diagnosis and minimally invasive transoral robotic surgery to remove their tumors.

21 Jan 2014